185 related articles for article (PubMed ID: 22532866)
1. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma.
Guan H; Singh NP; Singh UP; Nagarkatti PS; Nagarkatti M
PLoS One; 2012; 7(4):e35650. PubMed ID: 22532866
[TBL] [Abstract][Full Text] [Related]
2. CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome.
Park S; Lee S; Kim D; Kim H; Kwon YG
Front Pharmacol; 2023; 14():1242970. PubMed ID: 37711172
[No Abstract] [Full Text] [Related]
3. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma.
Guan H; Nagarkatti PS; Nagarkatti M
J Immunol; 2007 Sep; 179(6):3715-23. PubMed ID: 17785808
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
McQuade JL; Homsi J; Torres-Cabala CA; Bassett R; Popuri RM; James ML; Vence LM; Hwu WJ
BMC Cancer; 2018 Dec; 18(1):1274. PubMed ID: 30567529
[TBL] [Abstract][Full Text] [Related]
5. Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML
J Immunother; 2016; 39(9):355-366. PubMed ID: 27741090
[TBL] [Abstract][Full Text] [Related]
6. Complete response to high-dose IL-2 and enhanced IFNγ+Th17 : TREG ratio in a melanoma patient.
Diller ML; Kudchadkar RR; Delman KA; Lawson DH; Ford ML
Melanoma Res; 2016 Oct; 26(5):535-9. PubMed ID: 27467756
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18.
Salado C; Olaso E; Gallot N; Valcarcel M; Egilegor E; Mendoza L; Vidal-Vanaclocha F
J Transl Med; 2011 May; 9():59. PubMed ID: 21569399
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
Gallagher DC; Bhatt RS; Parikh SM; Patel P; Seery V; McDermott DF; Atkins MB; Sukhatme VP
Clin Cancer Res; 2007 Apr; 13(7):2115-20. PubMed ID: 17404094
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2.
Rafi-Janajreh AQ; Chen D; Schmits R; Mak TW; Grayson RL; Sponenberg DP; Nagarkatti M; Nagarkatti PS
J Immunol; 1999 Aug; 163(3):1619-27. PubMed ID: 10415067
[TBL] [Abstract][Full Text] [Related]
10. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Shablak A; Gilham DE; Hawkins RE; Elkord E
Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
[TBL] [Abstract][Full Text] [Related]
11. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2.
Chen X; Ai X; Wu C; Wang H; Zeng G; Yang P; Liu G
Cell Death Dis; 2018 Sep; 9(10):989. PubMed ID: 30250191
[TBL] [Abstract][Full Text] [Related]
12. Transient T cell depletion causes regression of melanoma metastases.
Rasku MA; Clem AL; Telang S; Taft B; Gettings K; Gragg H; Cramer D; Lear SC; McMasters KM; Miller DM; Chesney J
J Transl Med; 2008 Mar; 6():12. PubMed ID: 18334033
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
14. High-dose interleukin-2 therapy related adverse events and implications on imaging.
Shah NR; Declouette B; Ansari-Gilani K; Alhomoud MS; Hoimes C; Ramaiya NH; Güler E
Diagn Interv Radiol; 2021 Sep; 27(5):684-689. PubMed ID: 34559052
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth.
Niles RM; Cook CP; Meadows GG; Fu YM; McLaughlin JL; Rankin GO
J Nutr; 2006 Oct; 136(10):2542-6. PubMed ID: 16988123
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of resveratrol in a mouse model of melanoma lung metastasis.
Davoodvandi A; Darvish M; Borran S; Nejati M; Mazaheri S; Reza Tamtaji O; Hamblin MR; Masoudian N; Mirzaei H
Int Immunopharmacol; 2020 Nov; 88():106905. PubMed ID: 32905970
[TBL] [Abstract][Full Text] [Related]
17. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
18. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy.
Gores KM; Delsing AS; Kraus SJ; Powers L; Vaena DA; Milhem MM; Monick M; Doerschug KC
Shock; 2014 Aug; 42(2):115-20. PubMed ID: 24727870
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells.
Yang Y; Paik JH; Cho D; Cho JA; Kim CW
Int Immunopharmacol; 2008 Apr; 8(4):542-7. PubMed ID: 18328445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
